QQQ   444.60 (-0.05%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
QQQ   444.60 (-0.05%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
QQQ   444.60 (-0.05%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
QQQ   444.60 (-0.05%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
NASDAQ:NUWE

Nuwellis (NUWE) Stock Price, News & Analysis

$0.38
-0.02 (-4.77%)
(As of 10:28 AM ET)
Today's Range
$0.38
$0.41
50-Day Range
$0.39
$0.70
52-Week Range
$0.38
$5.73
Volume
149,364 shs
Average Volume
866,914 shs
Market Capitalization
$2.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Nuwellis MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
12.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Nuwellis in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.29) to ($1.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.22 out of 5 stars

NUWE stock logo

About Nuwellis Stock (NASDAQ:NUWE)

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama. Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

NUWE Stock Price History

NUWE Stock News Headlines

Maxim Group Keeps Their Buy Rating on Nuwellis (NUWE)
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Q4 2023 Nuwellis Inc Earnings Call
Earnings Preview For Nuwellis
Nuwellis Q4 Earnings Preview
Nuwellis earnings: here's what to expect
Nuwellis Inc NUWE
Nuwellis Stock (NASDAQ:NUWE), Short Interest Report
Nuwellis, Inc. (22SA.F)
See More Headlines
Receive NUWE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:NUWE
Fax
N/A
Employees
59
Year Founded
N/A

Profitability

Net Income
$-20,210,000.00
Net Margins
-227.99%
Pretax Margin
-227.90%

Debt

Sales & Book Value

Annual Sales
$8.86 million
Book Value
$0.53 per share

Miscellaneous

Free Float
6,741,000
Market Cap
$2.71 million
Optionable
Not Optionable
Beta
0.18
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Nestor Jaramillo Jr. (Age 67)
    President, CEO & Director
    Comp: $437.71k
  • Mr. Robert B. Scott (Age 44)
    Chief Financial Officer
    Comp: $252.6k
  • Mr. Neil P. Ayotte Esq. (Age 60)
    Senior VP, General Counsel, Secretary & Chief Compliance Officer
    Comp: $342.54k
  • Mr. John Kowalczyk
    Senior Vice President of Sales & Marketing
  • Ms. Sandra Eayrs
    Chief Human Resources Officer
  • Mr. Vitaliy Epshteyn (Age 46)
    Sr. Vice President of Operations & Engineering
  • Dr. John Lynn Jefferies FACC
    M.D., M.P.H., Chief Medical Officer & Member of Medical Advisory Board
  • Mr. Paul Wotta (Age 67)
    Corporate Controller

NUWE Stock Analysis - Frequently Asked Questions

Should I buy or sell Nuwellis stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuwellis in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NUWE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUWE, but not buy additional shares or sell existing shares.
View NUWE analyst ratings
or view top-rated stocks.

How have NUWE shares performed in 2024?

Nuwellis' stock was trading at $0.5809 at the start of the year. Since then, NUWE stock has decreased by 31.3% and is now trading at $0.3990.
View the best growth stocks for 2024 here
.

Are investors shorting Nuwellis?

Nuwellis saw a increase in short interest in March. As of March 15th, there was short interest totaling 866,300 shares, an increase of 22.2% from the February 29th total of 708,700 shares. Based on an average daily volume of 975,300 shares, the short-interest ratio is currently 0.9 days. Currently, 12.7% of the shares of the company are sold short.
View Nuwellis' Short Interest
.

When is Nuwellis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our NUWE earnings forecast
.

How were Nuwellis' earnings last quarter?

Nuwellis, Inc. (NASDAQ:NUWE) issued its quarterly earnings data on Tuesday, March, 5th. The company reported ($2.24) earnings per share for the quarter, missing analysts' consensus estimates of ($1.39) by $0.85. The company earned $2.55 million during the quarter. Nuwellis had a negative net margin of 227.99% and a negative trailing twelve-month return on equity of 218.79%. During the same quarter in the previous year, the business posted ($5.00) earnings per share.

When did Nuwellis' stock split?

Shares of Nuwellis reverse split before market open on Sunday, December 11th 2022. The 1-100 reverse split was announced on Sunday, December 11th 2022. The number of shares owned by shareholders was adjusted after the market closes on Sunday, December 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Who are Nuwellis' major shareholders?

Nuwellis' stock is owned by a number of institutional and retail investors. Top institutional investors include Virtu Financial LLC (1.67%), Vanguard Group Inc. (1.53%) and Vanguard Group Inc. (1.53%).
View institutional ownership trends
.

How do I buy shares of Nuwellis?

Shares of NUWE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NUWE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners